TABLE II.
Top 25 Most Significant Pathways
| Pathway | Pathway size (SNP count) IMAGE2/German ADHD GWAS | Methods with nominal significance | Median pooled P-value |
|---|---|---|---|
| Ca activated K+ channels* | 262/487 | 5 | 0.0010 |
| FGFR1b ligand binding and activation | 56/126 | 5 | 0.0011 |
| FGFR2b ligand binding and activation | 64/145 | 5 | 0.0023 |
| Potassium channels | 1065/2117 | 4 | 0.0026 |
| Signaling mediated by p38-gamma and p38-delta | 58/108 | 4 | 0.0043 |
| Validated targets of C-MYC transcriptional repression* | 243/548 | 5 | 0.0060 |
| RhoA signaling pathway | 295/507 | 4 | 0.0075 |
| tnf/stress related signaling | 111/217 | 5 | 0.0089 |
| Histidine degradation III* | 41/79 | 3 | 0.0113 |
| Dermatan sulfate biosynthesis | 85/206 | 4 | 0.0116 |
| Chondroitin sulfate biosynthesis | 219/451 | 4 | 0.0157 |
| Metabolism of angiotensinogen to angiotensins* | 70/143 | 3 | 0.0160 |
| Clearance of nuclear envelope membranes from chromatin* | 39/83 | 4 | 0.0165 |
| Histidine catabolism* | 21/52 | 4 | 0.0184 |
| FGFR1 ligand binding and activation | 69/166 | 5 | 0.0197 |
| RAC1 signaling pathway | 282/446 | 4 | 0.0197 |
| Regulation of signaling by CBL | 180/322 | 3 | 0.0224 |
| Caspase-mediated cleavage of cytoskeletal proteins | 128/208 | 4 | 0.0238 |
| FGFR2 ligand binding and activation | 81/201 | 4 | 0.0240 |
| Human cytomegalovirus and map kinase pathways | 69/143 | 3 | 0.0295 |
| Thromboxane A2 receptor signaling* | 821/1586 | 3 | 0.0299 |
| LKB1 signaling events | 305/482 | 3 | 0.0304 |
| FGFR ligand binding and activation | 103/243 | 3 | 0.0312 |
| Nitric oxide stimulates guanylate cyclase | 843/1710 | 4 | 0.0324 |
| Role of mal in rho-mediated activation of srf* | 66/107 | 3 | 0.0337 |
Pathways in bold were reported nominally significant by multiple methods in both the IMAGE2 and German ADHD GWAS datasets. Pathways marked with an* were also nominally significant by at least one method in the post-imputation analysis (Supplementary Tables S3 and S4). For each pathway the following information is provided: the number of SNPs assigned to the pathway in each data set, the number of analysis methods reporting the pathway nominally significant, and the median pooled P-value across all the analysis methods.